{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-008433","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.270897+00:00","generated_at":"2026-05-19T21:41:46.365087+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fortress closes sale of Checkpoint to Sun Pharma; receives ~$28M cash plus milestones","bullets":["Checkpoint merged into Sun Pharma on May 30, 2025; deconsolidated from Fortress.","Fortress gets ~$28.0M cash at close, up to $4.8M regulatory milestone, and quarterly royalty of 2.5% on certain product net sales.","Pro forma gain on deconsolidation is $26.6M; pro forma net loss attributable to common stockholders improves from $(0.48) to $0.57 per share for Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-008433","json":"https://secwatch.observer/filing/0001558370-25-008433.json","markdown":"https://secwatch.observer/filing/0001558370-25-008433.md","text":"https://secwatch.observer/filing/0001558370-25-008433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837025008433/0001558370-25-008433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837025008433/fbio-20250530x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T21:41:46.365087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a77504a26e06b96113a8f829649184251d47e916","claim":"Fortress Biotech, Inc. completed a disposition involving Sun Pharmaceutical Industries, Inc. for approximately $28.0 million in cash (closed 2025-05-30).","evidence_excerpt":"as a subsidiary of Fortress (the “Subsidiary Sale”). In connection with the closing of the Merger and pursuant to the Merger Agreement, Fortress will receive approximately $28.0 million in cash and be eligible to receive up to an additional $4.8 million upon achievement of a regulatory milestone associated with the rights (“CVRs”) issued under a Contingent Value","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000155837025008433/0001558370-25-008433-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Sun Pharmaceutical Industries, Inc."},{"label":"Consideration","value":"approximately $28.0 million in cash"},{"label":"Closing","value":"2025-05-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}